CHADS 2 , CHA 2 DS 2 -VASc, and long-term stroke outcome in patients without atrial fibrillation
Top Cited Papers
- 12 March 2013
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 80 (11), 1009-1017
- https://doi.org/10.1212/wnl.0b013e318287281b
Abstract
Objective: CHADS2 and CHA2DS2-VASc scores are used to assess stroke risk in patients with atrial fibrillation (AF). We investigated whether these scores are associated with stroke outcome in non-AF stroke patients. Methods: Consecutive patients with acute first-ever ischemic stroke but without AF were classified into subgroups according to prestroke CHADS2 and CHA2DS2-VASc scores and followed up for 5 years. The end points were death, stroke recurrence, and a composite of major cardiovascular events. Results: Among 1,756 patients (aged 67.2 ± 12.3 years, 68.2% males), there were 258 (14.7%), 617 (35.3%), and 878 (50.0%) patients with low, intermediate, and high CHADS2 score, respectively. The corresponding figures for CHA2DS2-VASc subgroups were 110 (6.3%), 255 (14.5%), and 1,391 (79.2%). There were significant differences between CHADS2 subgroups in 5-year mortality (log-rank test = 74.5, p < 0.0001), stroke recurrence (log-rank test = 12.3, p = 0.002), and cardiovascular events (log-rank test = 19.4, p < 0.001). Similarly, there were significant differences between CHA2DS2-VASc subgroups in 5-year mortality (log-rank test = 74.5, p < 0.0001), stroke recurrence (log-rank test = 10.6, p = 0.005), and cardiovascular events (log-rank test = 16.4, p < 0.001). Compared with the low-risk group, patients in intermediate- and high-risk CHADS2 subgroups had higher 5-year mortality (hazard ratio [HR]: 2.22 [95% confidence interval {CI}: 1.78–2.77] and 3.66 [95% CI: 2.38–5.62], respectively), stroke recurrence (HR: 1.74 [95% CI: 1.09–2.79] and 1.71 [95% CI: 1.08–2.71], respectively), and cardiovascular events (HR: 1.78 [95% CI: 1.23–2.57] and 1.86 [95% CI: 1.30–2.67], respectively). Compared with the low-risk group, patients in the high-risk CHA2DS2-VASc subgroup also had higher 5-year mortality (HR: 3.56, 95% CI: 1.89–6.70), stroke recurrence (HR: 2.93, 95% CI: 1.30–6.61), and cardiovascular events (HR: 2.71, 95% CI: 1.49–4.95). Conclusions: Prestroke CHADS2 and CHA2DS2-VASc scores predict long-term stroke outcomes in non-AF patients with acute ischemic stroke. These scores may provide a simple way of stroke prognostic risk stratification among non-AF stroke patients.This publication has 22 references indexed in Scilit:
- An integer-based score to predict functional outcome in acute ischemic strokeNeurology, 2012
- Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10‐year follow‐up studyEuropean Journal of Heart Failure, 2012
- Early neurological outcomes according to CHADS2 score in stroke patients with non‐valvular atrial fibrillationEuropean Journal of Neurology, 2011
- CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA RegistryJournal of the Neurological Sciences, 2011
- Survival after stroke — The impact of CHADS2 score and atrial fibrillationInternational Journal of Cardiology, 2010
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based ApproachSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in Acute StrokeJournal Of Stroke & Cerebrovascular Diseases, 2009
- Predictive value of the Essen Stroke Risk Score and Ankle Brachial Index in acute ischaemic stroke patients from 85 German stroke unitsJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Selecting Patients With Atrial Fibrillation for AnticoagulationCirculation, 2004
- Validation of Clinical Classification Schemes for Predicting StrokeJAMA, 2001